NCT03201276

Individual Differences in Glucosamine Sulfate Exposure Levels

Individual Differences in Glucosamine Sulfate Exposure Levels and Related Gene Polymorphism Research

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Glucosamine is an important part of the treatment strategy for osteoarthritis, but its effectiveness is still controversial. To explain the efficacy differences of glucosamine, in this study the investigators detect the concentration of glucosamine in the plasma and synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of glucosamine transporters. On the one hand, the investigators compare the plasma peak and gluten glucosamine concentration and the concentration in synovial fluid among participants to observe the individual differences of glucosamine exposure in vivo. On the other hand, the investigators investigate the correlation between drug concentrations, effect index and gene polymorphism. The hypothesis is that glucosamine exposure in vivo has individual differences and gene polymorphism can explain this differences.

Conditions

• Knee Osteoarthritis

Interventions

Type	Name	Description
DRUG	Glucosamine Sulfate	Patients taking glucosamine sulfate 1500mg every day for at least four days.

Timeline

• Start date: 2017-07-02
• Primary completion: 2019-07-01
• Completion: 2019-10-01
• First posted: 2017-06-28
• Last updated: 2017-07-05

Regulatory

• FDA-regulated drug study